Key Points. No clearance of mid-cycle-marrow blasts in patients with IDH2R172-mutated AML after intensive induction, despite later achieving CRKinetics of
Key PointsVen can be safely used in combination with 7+3 chemotherapy for remission induction in patients with newly diagnosed AML.Ven plus 7+3 chemotherap
In recent years, several novel CD3×CD20 bispecific immunotherapies have received accelerated approval for the treatment of follicular lymphoma and diffuse
Key PointsVen can be safely used in combination with 7+3 chemotherapy for remission induction in patients with newly diagnosed AML.Ven plus 7+3 chemotherap
In this issue of Blood Advances, Gauthier et al1 report on a phase 1 clinical trial conducted at Fred Hutchinson Cancer Research Center which tested…
In this issue of Blood Advances, Nieves et al1 present findings from SACRED (Stroke Avoidance for Children in República Dominicana; ClinicalTrials.gov iden
Key Points. Based on duration and timing of thrombocytopenia, we introduce T-ICAHT as a novel grading that expands on the existing N-ICAHT system.Severe (G
Abstract. In this study, we first analyzed data from 147 patients with solitary plasmacytomas treated at the Mayo Clinic between 2005 and 2022 and then…
